Please login to the form below

Not currently logged in
Email:
Password:

Sutent

This page shows the latest Sutent news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

This includes BMS’Opdivo plus Yervoy, which gained US approval last month and showed strong superiority in reducing the risk of death compared to current RCC standard, Pfizer’s Sutent.

Latest news

More from news
Approximately 4 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... The new trial of previously untreated patients with

  • Charting a course for expansion Charting a course for expansion

    In addition to meeting the primary endpoint of the study, the trial also showed median progression-free survival of 8.2 months versus Sutent's 5.6 months.

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV) and Pfizer's Sutent (cancer).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... This meant that due to lack of data, there was no benefit found for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics